Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer

Current and future immunotherapies for thyroid cancer

(2017) Alessandro Antonelli et al.   Expert Review of Anticancer Therapy

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

(2016) Marisa Dolled-Filhart et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer

(2016) Jill J. Bastman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

(2016) Laura Q.M. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

(2016) Subrata Chowdhury et al.   Oncotarget

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

(2015) Martin Schlumberger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) F. Pacini et al.   ANNALS OF ONCOLOGY

Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation

(2012) Lucas Leite Cunha et al.   ENDOCRINE-RELATED CANCER

2011: the immune hallmarks of cancer

(2011) Federica Cavallo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Dedifferentiated thyroid cancer: A therapeutic challenge

(2008) Alessandro Antonelli et al.   BIOMEDICINE & PHARMACOTHERAPY